Aryaman Capital Markets PAT jumps 167% YoY to ₹17.93 Cr, fuelled by investment gains
PAT +166.88% YoY · revenue +83.68% · margins expanding
₹20.93 Cr
+83.68% YoY
₹17.93 Cr
+166.88% YoY
84.74%
+25.8pp YoY
₹14.97
Aryaman Capital Markets reported standalone PAT of ₹17.93 Cr for Q2 FY27 (quarter ended 30-Sep-2026), up 166.9% YoY from ₹6.72 Cr and up 129.0% QoQ from ₹7.83 Cr, with EPS of ₹14.97 versus ₹5.61 a year ago. Revenue from operations rose 83.7% YoY to ₹20.93 Cr (up 125.5% QoQ from ₹9.28 Cr), and net profit margin expanded to 84.8% of total income from 58.97% a year earlier and 82.40% last quarter. YoY is the primary read here, and on that basis both lines expanded sharply — but the quality behind the expansion needs flagging.
Q2 FY-2027 vs prior quarters
The P&L itself carries a nil 'Exceptional Items' line, yet total expenses collapsed to just ₹0.27 Cr from ₹2.86 Cr a year ago, with no stock-in-trade purchases, inventory movement or finance costs this quarter — a materially different cost structure from the year-ago quarter, which carried ₹1.67 Cr of stock-in-trade purchases and ₹0.25 Cr of finance costs. The company's H1 FY27 cash flow statement shows ₹9.32 Cr of net fair-value/mark-to-market gains on investments versus nil in H1 FY26 — a key swing factor behind this year's jump — while the investment book grew to ₹93.21 Cr (30-Sep-26) from ₹82.47 Cr (31-Mar-26). The quarterly split of that gain isn't separately disclosed, so the headline growth should be read with this caveat: mark-to-market gains on an investment book are not the same as recurring brokerage or advisory fee income.
The stock went into the print at ₹470, up 13% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 2 consecutive quarters.
What the summary numbers don't show
Tax outgo ₹2.95 Cr (effective rate ~14.1%), mostly current tax of ₹2.73 Cr.
No exceptional items reported — standalone-only filer (single segment, no consolidated statement).
There is no prior management guidance or concall commentary on record for this company, and a search turned up no analyst/street consensus coverage for this microcap broker — so both vsGuidance and vsStreet are genuinely unknown rather than inferred. The quarter's other corporate developments — the 18th AGM (2-Sep-2026), a trading-window closure (25-Sep-2026) and KMP authorisation for materiality assessment (30-Sep-2026) — are routine governance/compliance matters unconnected to the earnings drivers. Going into Q3 FY27, the key question is whether the investment book's fair-value gains persist or reverse, since that — not a shift in the core brokerage/advisory cost base — is what moved this quarter's numbers.
W1
Whether the ₹9.32 Cr H1 FY27 fair-value gain on investments (vs nil in H1 FY26) repeats, moderates or reverses in H2 FY27.
W2
Core operating cost base, which fell to near-zero (₹0.27 Cr) this quarter from ₹2.86 Cr YoY — watch if stock-in-trade/trading activity and associated finance costs resume.
W3
Investment book size (₹93.21 Cr at Sep-26 vs ₹82.47 Cr at Mar-26) as the base against which future fair-value swings will be measured.